
A new paradigm: What oral anti-inflammatory therapy means for prescribers and payers
DPP-1 inhibitors are oral small molecules that block the enzyme responsible for activating neutrophil elastase, and in the pivotal ASPEN trial, brensocatib reduced annualized exacerbations by about 20% versus placebo.
Episodes in this series

Sala described the shift as notable because most prior innovation in bronchiectasis has been delivered through the bronchial tubes themselves — nebulizers and nebulized antibiotics. A DPP-1 inhibitor, by contrast, is an oral anti-inflammatory pill, used to supplement azithromycin in appropriate patients rather than replace it.
On what payers should be asking, Sala noted that brensocatib (brand name Brinsupri) has been commercially available since August 2025. The questions he hears most often from payers and managed care stakeholders center on the drug's cost, its cost-effectiveness, and appropriate use across the eligible patient population — unsurprising, he said, given that newly launched drugs are typically expensive at first.
For medical and pharmacy directors evaluating the mechanism against existing standards of care, Sala framed DPP-1 inhibition as genuinely novel — the first drug in its class for bronchiectasis, with more agents potentially following. Given how limited current options are, he argued the mechanism should be viewed as additive to the existing treatment toolkit rather than measured strictly against it, offering a parallel strategy in a field that has lacked good alternatives.
Related to this article







